Statin meta-analysis
This article was originally published in The Tan Sheet
Executive Summary
Statin therapy "can reduce the five-year incidence of major coronary events and stroke by about one fifth per mmol/L reduction in LDL cholesterol," according to a prospective meta-analysis published online by The Lancet Sept. 27. The study analyzed the results of 14 randomized trials such as AFCAPS, ALERT and ASCOT, and involved a total of more than 90,000 patients. Among the deaths caused by coronary heart disease, 1,548 were in the statin treatment group while 1,960 were in the control group. The results "are consistent with there being an approximately linear relationship between the absolute reductions in LDL cholesterol achieved in these trials and the proportional reductions in the incidence of coronary and other major vascular events," the Cholesterol Treatment Trialists' Collaboration concludes. "Statin therapy produced a clear reduction in all-cause mortality," they add...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.